Hjem › Tripelnegativ brystkreft › Maryland › Baltimore
Kliniske studier for Tripelnegativ brystkreft i Baltimore, MD
12 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Baltimore (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RekruttererFase 3
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekruttererFase 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekruttererFase 1
- United Theranostics, Glen Burnie · 9 mi unna
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RekruttererFase 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- og 1 flere
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
RekruttererFase 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruttererFase 2/3
- Local Institution - 1035, Baltimore
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
RekruttererFase 1
- United Theranostics, Glen Burnie · 9 mi unna
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RekruttererFase 1/2
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RekruttererFase 2
- University of Maryland Medical Center (UMMC), Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
RekruttererFase 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Baltimore
- Ikke-småcellet lungekreft60 studier
- Brystkreft47 studier
- Prostatakreft43 studier
- Lungekreft40 studier
- Kreft (alle typer)37 studier
- Pankreaskreft31 studier
- Kolorektal kreft31 studier
- Metastatisk kreft28 studier
- Fedme26 studier
- Blærekreft24 studier
- Hjertesvikt24 studier
- Eggstokkreft22 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.